Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clostridium Butyricum and Bacillus Coagulans for H. pylori Eradication
NCT03857425Phase 4Completed
- Sponsor
- Xijing Hospital of Digestive Diseases
- Start
- Mar 2019
- Primary completion
- Aug 2019
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 4, randomised trial of clostridium butyricum and bacillus coagulans in Helicobacter pylori infection (3 arms), sponsored by Xijing Hospital of Digestive Diseases. Primary endpoint: Helicobacter pylori eradication at 8 weeks. Started Mar 2019; status: completed.
02
Drugs
clostridium butyricumbacillus coagulans
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on NCT03857425.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03857425.